Patent application number | Description | Published |
20090117171 | Compositions and methods for treatment of macular degeneration and related conditions - The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. | 05-07-2009 |
20090220572 | Injectable Combination Therapy for Eye Disorders - The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors. | 09-03-2009 |
20100166862 | Local Complement Inhibition for Treatment of Complement-Mediated Disorders - The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof. | 07-01-2010 |
20110092446 | COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA - The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma. | 04-21-2011 |
20110182877 | SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS - The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber. | 07-28-2011 |
20110190221 | MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA - The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury. | 08-04-2011 |
20120135430 | COMPLEMENT ASSAYS AND USES THEREOF - The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods. | 05-31-2012 |
20120225114 | Modifying Macrophage Phenotype for Treatment of Disease - The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis. | 09-06-2012 |
20130072442 | Viral Complement Control Proteins for Eye Disorders - The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject. | 03-21-2013 |
20130149670 | METHODS, ARTICLES AND KITS FOR ALLERGIC DESENSITIZATION, VIA THE ORAL MUCOSA - Compositions and methods of use for desensitizing a subject to an allergen via regions of the oral mucosa are provided. | 06-13-2013 |
20130203678 | COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN - In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously. | 08-08-2013 |
20130218132 | Methods and Articles for Preventing or Reducing Risk of Developing a Hyperallergenic Immune System - Infant pacifiers, compositions, and methods of use thereof, for preventing or reducing risk of developing a hyperallergenic immune system or allergic condition are provided. | 08-22-2013 |
20130296254 | COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS - The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions. | 11-07-2013 |
20130324482 | COMPSTATIN ANALOGS FOR TREATMENT OF RHINOSINUSITIS AND NASAL POLYPOSIS - In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray. | 12-05-2013 |
20140050739 | LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS - The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof. | 02-20-2014 |
20140323407 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF - In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. | 10-30-2014 |
20140371133 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS - In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma. | 12-18-2014 |
20150150945 | Modifying Macrophage Phenotype for Treatment of Disease - The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis. | 06-04-2015 |
20160067357 | DETECTION OF HIGH RISK DRUSEN - In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided. In some aspects, presence of one or more high risk drusen in an eye indicates increased likelihood of developing AMD, GA, or advanced AMD or increased likelihood of rapid progression of AMD. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments methods comprise detecting Th17 cells or a Th17 biomarker in a body fluid. In some embodiments the Th17 biomarker is a cytokine. Methods may be applied individually or in any combination. In some embodiments any of the methods further comprises treating a subject at risk of developing AMD, GA, or advanced AMD or at increased likelihood of rapid progression of AMD with a complement inhibitor. In some aspects, agents useful for performing one or more of the methods are described. | 03-10-2016 |
Patent application number | Description | Published |
20110154323 | Controlling Depth and Latency of Exit of a Virtual Processor's Idle State in a Power Management Environment - A mechanism is provided in a logically partitioned data processing system for controlling depth and latency of exit of a virtual processor's idle state. A virtualization layer generates a cede latency setting information (CLSI) data. Responsive to booting a logical partition, the virtualization layer communicates the CLSI data to an operating system (OS) of the logical partition. The OS determines, based on the CLSI data, a particular idle state of a virtual processor under a control of the OS. Responsive to the OS calling the virtualization layer, the OS communicates the particular idle state of the virtual processor to the virtualization layer for assigning the particular idle state and wake-up characteristics to the virtual processor. | 06-23-2011 |
20120079500 | PROCESSOR USAGE ACCOUNTING USING WORK-RATE MEASUREMENTS - Accounting charges are assigned to workloads by measuring a relative use of computing resources by the workloads, then scaling the results using determined work-rate for the corresponding workload. Usage metrics for the individual resources may be selectable for the resources being measured and the work-rates may be determined from an analytical model or from empirical model that determines work-rates from an indication of processor throughput. Under single workload conditions on a platform, or other suitable conditions, a workload type may be used to select the particular usage metrics applied for the various resources. | 03-29-2012 |
20120096293 | Directed Resource Folding for Power Management - A mechanism is provided for directed resource folding for power management. The mechanism receives a set of static platform characteristics and a set of dynamic platform characteristics for a set of resources associated with the data processing system thereby forming characteristic information. The mechanism determines whether one or more conditions have been met for each resource in the set of resources using the characteristic information. Responsive to the one or more conditions being met, the mechanism performs a resource optimization to determine at least one of a first subset of resources in the set of resources to keep active and a second subset of resources in the set of resources to dynamically fold. Based on the resource optimization, the mechanism performs either a virtual resource optimization to optimally schedule the first subset of resources or a physical resource optimization to dynamically fold the second subset of resources. | 04-19-2012 |
20120137118 | Automatic Configuration Sampling for Managing Configuration Parameters of a Computer System - A computer configuration utility automatically alters system configuration parameters to sample multiple different configurations. At least one workrate metric is measured at each sampled configuration. The workrate measurements for the multiple different configurations are compared to determine the effect of different configurations with respect to at least one optimization criterion. System configuration is automatically adjusted to the optimum configuration. Preferably, the workrate metric is (non-idle) instructions executed per unit of time. | 05-31-2012 |
20120198452 | CONTROLLING DEPTH AND LATENCY OF EXIT OF A VIRTUAL PROCESSOR'S IDLE STATE IN A POWER MANAGEMENT ENVIRONMENT - A mechanism is provided in a logically partitioned data processing system for controlling depth and latency of exit of a virtual processor's idle state. A virtualization layer generates a cede latency setting information (CLSI) data. Responsive to booting a logical partition, the virtualization layer communicates the CLSI data to an operating system (OS) of the logical partition. The OS determines, based on the CLSI data, a particular idle state of a virtual processor under a control of the OS. Responsive to the OS calling the virtualization layer, the OS communicates the particular idle state of the virtual processor to the virtualization layer for assigning the particular idle state and wake-up characteristics to the virtual processor. | 08-02-2012 |
20130152098 | TASK PRIORITY BOOST MANAGEMENT - According to one aspect of the present disclosure, a method and technique for task priority boost management is disclosed. The method includes: responsive to a thread executing in user mode an instruction to boost a priority of the thread, accessing a boost register, the boost register accessible in kernel mode; determining a value of the boost register; and responsive to determining that the boost register holds a non-zero value, boosting the priority of the thread. | 06-13-2013 |
20130159693 | Automatic Configuration Sampling for Managing Configuration Parameters of a Computer System - A computer configuration utility automatically alters system configuration parameters to sample multiple different configurations. At least one workrate metric is measured at each sampled configuration. The workrate measurements for the multiple different configurations are compared to determine the effect of different configurations with respect to at least one optimization criterion. System configuration is automatically adjusted to the optimum configuration. Preferably, the workrate metric is (non-idle) instructions executed per unit of time. | 06-20-2013 |